tbuckley/cabot-search huggingface dataset:
Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response
Authors: Jennifer L. Johnson, Loredana Stoica, Yuwei Liu, Ping Jun Zhu, Abhisek Bhattacharya, Shelly A. Buffington, Redwan Huq, N. Tony Eissa, Ola Larsson, Bo T. Porse, Deepti Domingo, Urwah Nawaz, Renee Carroll, Lachlan Jolly, Tom S. Scerri, Hyung-Goo Kim, Amanda Brignell, Matthew J. Coleman, Ruth Braden, Usha Kini, Victoria Jackson, Anne Baxter, Melanie Bahlo, Ingrid E. Scheffer, David J. Amor, Michael S. Hildebrand, Penelope E. Bonnen, Christine Beeton, Jozef Gecz, Angela T. Morgan, Mauro Costa-Mattioli
Journal: Neuron (2019)

Highlights•Humans carrying novel variants in UPF2 exhibit speech and language deficits•Upf2-deficient mice and flies have impaired NMD and exhibit behavioral deficits•Inhibition of Upf2-dependent NMD triggers immune activation in mice•Reduction of brain inflammation reverses synaptic and behavioral deficitsSummaryIn humans, disruption of nonsense-mediated decay (NMD) has been associated with neurodevelopmental disorders (NDDs) such as autism spectrum disorder and intellectual disability. However, the mechanism by which deficient NMD leads to neurodevelopmental dysfunction remains unknown, preventing development of targeted therapies. Here we identified novel protein-coding UPF2 (UP-Frameshift 2) variants in humans with NDD, including speech and language deficits. In parallel, we found that mice lacking Upf2 in the forebrain (Upf2 fb-KO mice) show impaired NMD, memory deficits, abnormal long-term potentiation (LTP), and social and communication deficits. Surprisingly, Upf2 fb-KO mice exhibit elevated expression of immune genes and brain inflammation. More importantly, treatment with two FDA-approved anti-inflammatory drugs reduced brain inflammation, restored LTP and long-term memory, and reversed social and communication deficits. Collectively, our findings indicate that impaired UPF2-dependent NMD leads to neurodevelopmental dysfunction and suggest that anti-inflammatory agents may prove effective for treatment of disorders with impaired NMD.Graphical abstract
Role of Patient Maximizing-Minimizing Preferences in Thyroid Cancer Surveillance
Authors: Joshua M. Evron, David Reyes-Gastelum, Mousumi Banerjee, Laura D. Scherer, Lauren P. Wallner, Ann S. Hamilton, Kevin C. Ward, Sarah T. Hawley, Brian J. Zikmund-Fisher, Megan R. Haymart
Journal: Journal of Clinical Oncology (2019)

PURPOSE To understand the effect of patient preferences on thyroid cancer surveillance intensity. PATIENTS AND METHODS Eligible patients diagnosed with thyroid cancer between January 1, 2014, and December 31, 2015, from the Georgia and Los Angeles County SEER registries were surveyed between February 2017 and October 2018 (N = 2,632; response rate, 63%). Patient reports on health care utilization in the past year and responses to the validated Medical Maximizer-Minimizer Scale were linked to SEER data in the 2,183 disease-free patients. Ordered logistic regression was performed using a cumulative logit with nonproportional odds. RESULTS Of disease-free patients, 31.6% were classified as minimizers, 42.5% as moderate maximizers, and 25.9% as strong maximizers. In the past year, 25.2%, 27.3%, and 38.5% of minimizers, moderate maximizers, and strong maximizers, respectively, had ≥ 4 doctor visits, and 18.3%, 24.9%, and 29.5%, respectively, had ≥ 2 neck ultrasounds. When controlling for age, sex, race and ethnicity, comorbidity, stage, and SEER site, strong maximizers (compared with minimizers) were significantly more likely to report ≥ 4 doctor visits (odds ratio [OR], 1.45; 95% CI, 1.10-1.92), ≥ 2 neck ultrasounds (OR, 1.58; 95% CI, 1.17-2.14), ≥ 1 radioactive iodine scan (OR, 1.73; 95% CI, 1.19-2.50), and ≥ 1 additional imaging study (OR, 2.06; 95% CI, 1.56-2.72). CONCLUSION Among patients with thyroid cancer who have been declared disease free, preference for a more maximal versus minimal approach to medical care is associated with increased number of physician visits and imaging tests. Because increased surveillance does not clearly correlate with improved outcomes, poses potential risks to patients, and contributes to increased healthcare costs, stronger consideration of the role of patient preferences is necessary when framing discussions on surveillance.
ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Authors: C. Marth, C. Vulsteke, M.J. Rubio, V. Makker, E.I. Braicu, I.A. McNeish, M. Radoslaw, A. Ayhan, K. Hasegawa, X. Wu, L. Dutta, C. Xu, S.M. Keefe, J. Lee, S. Pignata
Journal: Annals of Oncology (2019)
Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies
Authors: Betul Oran, Kai Cao, Rima M. Saliba, Chitra M. Hosing, Uday R. Popat, Marcos de Lima, Yudith Carmazzi, Amin Alousi, Partow Kebriaei, Yago Nieto, Gabriela Rondon, Dana Willis, Nina Shah, Simrit Parmar, Amanda Olson, Brandt Moore, Richard E. Champlin, Katayoun Rezvani, Elizabeth J Shpall
Journal: Blood (2014)
Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Authors: L.-Y. Bai, C.-Y. Wu, P.-C. Chu, J.-R. Weng, C.-F. Chiu
Journal: Annals of Oncology (2019)
18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti–PD-1 Treatment for Melanoma
Authors: Wouter W. van Willigen, Winald R. Gerritsen, Erik H.J.G. Aarntzen
Journal: Clinical Nuclear Medicine (2019)

Abstract We report a case of a 50-year-old woman treated with anti–PD-1 inhibition for metastatic melanoma. During treatment, extensive and transient histopathologically confirmed sarcoid-like reaction was detected in multiple organ systems and at different time points using 18 F-FDG PET/CT imaging. Immune-related adverse events during anti-PD-1/PD-L1 antibody treatment are increasingly being reported. This case report emphasizes the broad spectrum of possible presentations of sarcoid-like reaction detected by 18 F-FDG PET/CT and its evolution in time. For the clinician, awareness of these immune-related adverse events helps to accurately interpret findings on imaging.
Real-world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
Authors: S. Cedres, J.D. Assaf, P. Iranzo, A. Callejo, N. Pardo, A. Navarro, A. Martinez-Marti, G. Rodriguez, V. Monton, J. Gonzalo, J.M. Miquel, A. Pedrola, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2019)
Evaluation of minimal important difference (MID) for the European organisation for research and treatment of cancer (EORTC) pancreatic cancer module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Authors: M. Reni, J. Braverman, A. Hendifar, C.-P. Li, T. Macarulla Mercade, D.-Y. Oh, H. Riess, M.A. Tempero, B. Lu, J. Marcus, N. Joshi, M. Botterman, A.C. Dueck
Journal: Annals of Oncology (2019)
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors
Authors: Mark D. Pegram, David Miles, C. Kimberly Tsui, Yu Zong
Journal: Clinical Cancer Research (2019)

Efficacy data from the KATHERINE clinical trial, comparing the HER2-directed antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to trastuzumab in patients with early-stage HER2-amplified/overexpressing breast cancer with residual disease after neoadjuvant therapy, demonstrates superiority of T-DM1 (HR for invasive disease or death, 0.50; P < 0.001). This establishes foundational precedent for ADCs as effective therapy for treatment of subclinical micrometastasis in an adjuvant (or post-neoadjuvant) early-stage solid tumor setting. Despite this achievement, general principles from proposed systems pharmacokinetic modeling for intracellular processing of ADCs indicate potential shortcomings of T-DM1: (i) Cmax limited by toxicities; (ii) slow internalization rate; (iii) resistance mechanisms due to defects in intracellular trafficking [loss of lysosomal transporter solute carrier family 46 member 3, (SLC46A3)], and increased expression of drug transporters MDR1 and MRP1; and (iv) lack of payload bystander effects limiting utility in tumors with heterogeneous HER2 expression. These handicaps may explain the inferiority of T-DM1-based therapy in the neoadjuvant and first-line metastatic HER2+ breast cancer settings, and lack of superiority to chemotherapy in HER2+ advanced gastric cancer. In this review, we discuss how each of these limitations is being addressed by manipulating internalization and trafficking using HER2:HER2 bispecific or biparatopic antibody backbones, using site-specific, fixed DAR conjugation chemistry, and payload swapping to exploit alternative intracellular targets and to promote bystander effects. Newer HER2-directed ADCs have impressive clinical activity even against tumors with lower levels of HER2 receptor expression. Finally, we highlight ongoing clinical efforts to combine HER2 ADCs with other treatment modalities, including chemotherapy, molecularly targeted therapies, and immunotherapy.
Work related empowerment and collaboration in multiprofessional cancer centre
Authors: V. Sulosaari, P. Ahonen, H. Heikkilä, A. Jekunen, H. Leino-Kilpi, P. Rautava, M. Rekunen, M. Siekkinen, M. Stolt, T. Vahlberg, L. Walta
Journal: Annals of Oncology (2019)
AB1028 MYOCARDITIS IN PEDIATRIC LUPUS: A CLINICAL CONUNDRUM
Authors: Johnson Nameirakpam, Anjani Gummadi, Rakesh Kumar, Deepti Suri, Amit Rawat, Surjit Singh
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Myocarditis in pediatric lupus is uncommon but carry a significant morbidity and mortality. <h3>Objectives</h3> To study the clinical profile and outcome of children with lupus myocarditis <h3>Methods</h3> We reviewed our cohort of children with lupus registered between January 1993 to November 2018. Of the 140 lupus patients that were diagnosed during this time, 3 had myocarditis. <h3>Results</h3> Patient 1 was an 11-year-old girl who presented with fever, rash and generalized body swelling for 3 months. Physical examinations revealed heart rate 148/min, respiratory rate 30/min, and blood pressure (BP) 100/80 mmHg. She had pallor, malar rash, hepatomegaly and gallop rhythm. Investigations are detailed in the table. She received intravenous immunoglobulin and initiated on pulse methylprednisolone and followed by pulse intravenous cyclophosphamide. She was discharged on oral prednisolone and subsequently tapered. Patient 2 was a 9-year-old girl presented with fever and rash for 3 months with lethargy for 1 day. She had pallor, malar rash, hepatomegaly. Physical examinations revealed heart rate 132/min, respiratory rate 32/min, feeble peripheral pulses and BP 100/80 mmHg. She received intravenous cyclophosphamide monthly for 6 months along with oral prednisolone in tapering dose. Patient 3 was a 12-year-old girl, who was known to have SLE for 2 months, presented with fever, malar rash, and photosensitivity. She had stopped taking steroids for 2 weeks. On examination, she had heart rate 122/min, respiratory rate 28/min and BP 100/72 mmHg. She had pallor, alopecia, oral ulcers, malar rash, gallop rhythm and tender hepatomegaly. She was given pulse methylprednisolone and furosemide therapy followed by oral prednisolone in gradually tapering dose. <h3>Conclusion</h3> Myocarditis in lupus is uncommon but carries a significant morbidities. The presence of global hypokinesia with a low ejection fraction on two dimensional echocardiography (2DE) is a strong pointer towards the diagnosis. Immunosuppressant drugs with supportive therapy remain the preferred treatment. Early diagnosis and prompt treatment may be very rewarding. <h3>References</h3> [1] Chang JC, Xiao R, Mercer-Rosa L, Knight AM, Weiss PF. Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. Lupus. 2018 Nov;27(13):2146–54. <h3>Disclosure of Interests</h3> None declared
Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Authors: A.K. Turnbull, M.A. Inda, A. van de Stolpe, D. Keizer, D. Clout, H. van Zon, M. Akse, A. Fernando, C. Martinez-Perez, J.M. Dixon, A.H. Sims
Journal: Annals of Oncology (2019)
Harmonization study of tumour mutational burden determination in non-small cell lung cancer (NSCLC)
Authors: E.M. Garrido-Martin, J. Ramos-Paradas, S. Hernandez Prieto, E. Sanchez, A. Rosado, T. Caniego-Casas, N. Carrizo, A.B. Enguita, M.T. Muñoz-Jiménez, B. Rodriguez, U. Perez-Gonzalez, D. Gomez Sanchez, I. Ferrer, S. Ponce Aix, A. Nuñez Buiza, P. Garrido, J. Palacios, F. Lopez-Rios, L. Paz-Ares
Journal: Annals of Oncology (2019)
Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor &amp; HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Authors: L. Biganzoli, E. Brain, L. Malorni, E. Risi, M.M. Regan
Journal: Annals of Oncology (2019)
TCT-23 Heterogeneity of Debris Captured by Cerebral Embolic Protection Filters During Transcatheter Aortic Valve Replacement With Different Transcatheter Heart Valves
Authors: Herbert Kroon, Jan von der Thusen, Maarten van Wiechen, Joris Ooms, Lennart van Gils, Joost Daemen, Nicolas Van Mieghem
Journal: Journal of the American College of Cardiology (2019)
心房細動による頻脈誘発性心筋症に対し,電気的除細動と肺静脈隔離術により,心機能の改善を認めた1例
Authors: 有川亮, 二宮雄一, 八反田和美, 石田実雅, 松下毅彦, 桶谷直也, 市来仁志, 奥井英樹, 新里拓郎, 才原啓司, 福留剛, 小川正一, 片岡哲郎, 濱崎秀一, 鄭忠和, 植屋奈美, 平川立身
Journal: Circulation (2007)
Small GTP-Binding Protein GDP Dissociation Stimulator Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells
Authors: Masamichi Nogi, Kimio Satoh, Shinichiro Sunamura, Nobuhiro Kikuchi, Taijyu Satoh, Ryo Kurosawa, Junichi Omura, Md. Elias-Al-Mamun, Mohammad Abdul Hai Siddique, Kazuhiko Numano, Shun Kudo, Satoshi Miyata, Masatoshi Akiyama, Kiichiro Kumagai, Shunsuke Kawamoto, Yoshikatsu Saiki, Hiroaki Shimokawa
Journal: Circulation (2018)

Thoracic aortic aneurysm (TAA) and dissection are fatal diseases that cause aortic rupture and sudden death. The small GTP-binding protein GDP dissociation stimulator (SmgGDS) is a crucial mediator of the pleiotropic effects of statins. Previous studies revealed that reduced force generation in aortic smooth muscle cells (AoSMCs) causes TAA and thoracic aortic dissection.To examine the role of SmgGDS in TAA formation, we used an angiotensin II (1000 ng·min-1·kg-1, 4 weeks)-induced TAA model.We found that 33% of Apoe-/- SmgGDS+/- mice died suddenly as a result of TAA rupture, whereas there was no TAA rupture in Apoe-/- control mice. In contrast, there was no significant difference in the ratio of abdominal aortic aneurysm rupture between the 2 genotypes. We performed ultrasound imaging every week to follow up the serial changes in aortic diameters. The diameter of the ascending aorta progressively increased in Apoe-/- SmgGDS+/- mice compared with Apoe-/- mice, whereas that of the abdominal aorta remained comparable between the 2 genotypes. Histological analysis of Apoe-/- SmgGDS+/- mice showed dissections of major thoracic aorta in the early phase of angiotensin II infusion (day 3 to 5) and more severe elastin degradation compared with Apoe-/- mice. Mechanistically, Apoe-/- SmgGDS+/- mice showed significantly higher levels of oxidative stress, matrix metalloproteinases, and inflammatory cell migration in the ascending aorta compared with Apoe-/- mice. For mechanistic analyses, we primary cultured AoSMCs from the 2 genotypes. After angiotensin II (100 nmol/L) treatment for 24 hours, Apoe-/- SmgGDS+/- AoSMCs showed significantly increased matrix metalloproteinase activity and oxidative stress levels compared with Apoe-/- AoSMCs. In addition, SmgGDS deficiency increased cytokines/chemokines and growth factors in AoSMCs. Moreover, expressions of fibrillin-1 ( FBN1), α-smooth muscle actin ( ACTA2), myosin-11 ( MYH11), MYLLK, and PRKG1, which are force generation genes, were significantly reduced in Apoe-/- SmgGDS+/- AoSMCs compared with Apoe-/- AoSMCs. A similar tendency was noted in AoSMCs from patients with TAA compared with those from control subjects. Finally, local delivery of the SmgGDS gene construct reversed the dilation of the ascending aorta in Apoe-/- SmgGDS+/- mice.These results suggest that SmgGDS is a novel therapeutic target for the prevention and treatment of TAA.
Abstract 15051: Selective Suppression of Aldosterone Production in Non-Human Primates by SE-6440, a Potent and Highly-Selective Inhibitor of Aldosterone Synthase (CYP11B2)
Authors: J David Becherer, Edward P Garvey, William J Hoekstra, Robert J Schotzinger, Steven M Sparks
Journal: Circulation (2018)

Introduction: Primary aldosteronism (PA) is a major public health concern given its prevalence and associated cardiovascular and renal pathology. Compared to patients with essential hypertension, p...
CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Authors: L. Paz-Ares, E.B. Garon, A. Ardizzoni, F. Barlesi, B.C. Cho, G. de Castro Junior, P. De Marchi, E. Felip, Y. Goto, A. Greystoke, S. Lu, D W-T Lim, V.A. Papadimitrakopoulou, M. Reck, B.J. Solomon, D. Spigel, D.S.W. Tan, M. Thomas, J C-H Yang, B. Johnson
Journal: Annals of Oncology (2019)
Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Authors: L. Harshyne, A. Luginbuhl, J.M. Curry, Y. Kim, A. Argiris, S. Shukla, U. Rodeck, J.M. Johnson
Journal: Annals of Oncology (2019)
Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome
Authors: Julien Zuber, Marie Frimat, Sophie Caillard, Nassim Kamar, Philippe Gatault, Florent Petitprez, Lionel Couzi, Noemie Jourde-Chiche, Valérie Chatelet, Raphael Gaisne, Dominique Bertrand, Jamal Bamoulid, Magali Louis, Rebecca Sberro Soussan, David Navarro, Pierre-Francois Westeel, Luc Frimat, Charlotte Colosio, Antoine Thierry, Joseph Rivalan, Laetitia Albano, Nadia Arzouk, Emilie Cornec-Le Gall, Guillaume Claisse, Michelle Elias, Khalil El Karoui, Sophie Chauvet, Jean-Philippe Coindre, Jean-Philippe Rerolle, Leila Tricot, Johnny Sayegh, Cyril Garrouste, Christophe Charasse, Yahsou Delmas, Ziad Massy, Maryvonne Hourmant, Aude Servais, Chantal Loirat, Fadi Fakhouri, Claire Pouteil-Noble, Marie-Noelle Peraldi, Christophe Legendre, Eric Rondeau, Moglie Le Quintrec, Véronique Frémeaux-Bacchi
Journal: Journal of the American Society of Nephrology (2019)

Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence rates after kidney transplant, with devastating outcomes. In late 2011, experts in France recommended the use of highly individualized complement blockade-based prophylaxis with eculizumab to prevent post-transplant atypical HUS recurrence throughout the country.To evaluate this strategy's effect on kidney transplant prognosis, we conducted a retrospective multicenter study from a large French nationwide registry, enrolling all adult patients with atypical HUS who had undergone complement analysis and a kidney transplant since January 1, 2007. To assess how atypical HUS epidemiology in France in the eculizumab era evolved, we undertook a population-based cohort study that included all adult patients with atypical HUS (n=397) between 2007 and 2016.The first study included 126 kidney transplants performed in 116 patients, 58.7% and 34.1% of which were considered to be at a high and moderate risk of atypical HUS recurrence, respectively. Eculizumab prophylaxis was used in 52 kidney transplants, including 39 at high risk of recurrence. Atypical HUS recurred after 43 (34.1%) of the transplants; in four cases, patients had received eculizumab prophylaxis and in 39 cases they did not. Use of prophylactic eculizumab was independently associated with a significantly reduced risk of recurrence and with significantly longer graft survival. In the second, population-based cohort study, the proportion of transplant recipients among patients with ESKD and atypical HUS sharply increased between 2012 and 2016, from 46.2% to 72.3%, and showed a close correlation with increasing eculizumab use among the transplant recipients.Results from this observational study are consistent with benefit from eculizumab prophylaxis based on pretransplant risk stratification and support the need for a rigorous randomized trial.
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
Authors: Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead
Journal: Blood (2019)
Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Authors: A.Z. Bujak, C.-F. Weng, M.-J. Silva, M. Yeung, L. Lo, S. Ftouni, C. Litchfield, A. Ko, K. Kuykhoven, C. van Geelen, S. Chandrashekar, M.A. Dawson, S. Loi, S.Q. Wong, S.-J. Dawson
Journal: Annals of Oncology (2019)
Preventing suicide in medical staff: fix working conditions
Authors: Gabrielle V Pendlebury
Journal: BMJ (2019)

Gerada calls for better suicide prevention for medical staff . 1 The Society of Occupational Medicine’s recent report on the mental health of UK doctors notes that occupational and individual factors (such as emotional labour, personality, and coping styles) contribute to distress in doctors but that poor working conditions seem to have the strongest effect on wellbeing. …
Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer: A retrospective case-control study of 355 cases with biomarker analysis
Authors: M. Tiako Meyo, M. Lavigne, P. Leclerc, M.-L. Tanguy, Y. Kirova, A. Hurgon, A. Lalli, V. Fourchotte, A. Vincent-Salomon, L. Escalup, P.H. Cottu
Journal: Annals of Oncology (2019)
Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Authors: E. Castro, R Lozano Mejorada, M. Saez, U.F.F. De Giorgi, I. Aragón, N Romero Laorden, G.A. De Velasco Oria de Rueda, L. Magraner, M.I. Pacheco, J. Puente, A González del Alba, P Borrega Garcia, V. Conteduca, J C Villa Guzman, E Fernandez Parra, A. Rodriguez-Vida, A Medina Colmenero, R Morales Barrera, D. Lorente, D Olmos Hidalgo
Journal: Annals of Oncology (2019)